INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid
Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD
The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) stock prior to
January 18, 2017.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the
sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. (NYSE: LLY). Under the terms of the transaction (valued at
approximately $960 Million) CoLucid Pharmaceuticals, Inc. shareholders will receive $46.50 for each share of CoLucid
Pharmaceuticals, Inc. they own. To learn more about the action and your rights, go to:
http://zlk.9nl.com/CoLucid_CLCD
or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by
telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The
firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors
throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders.
For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not
guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170127005432/en/